Ascendis Pharma A/S (NASDAQ:ASND) Sets New 52-Week High – Should You Buy?

Ascendis Pharma A/S (NASDAQ:ASND) reached a new 52-week high on Monday . The company traded as high as $168.74 and last traded at $167.04, with a volume of 130347 shares traded. The stock had previously closed at $152.98.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald upped their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Evercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, The Goldman Sachs Group boosted their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Price Performance

The business has a 50-day simple moving average of $139.43 and a 200-day simple moving average of $135.09. The firm has a market capitalization of $9.99 billion, a PE ratio of -23.19 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently modified their holdings of the business. Virtus ETF Advisers LLC increased its holdings in Ascendis Pharma A/S by 3.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 100 shares during the period. Legato Capital Management LLC increased its holdings in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares during the period. Jones Financial Companies Lllp increased its holdings in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $28,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $30,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.